drugset / Trial / NCT04028050

A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

NCT04028050

Phase 3 Completed 155 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelTreatment

Summary

This is a phase IIIB, single-arm, single-country, multicenter study of the safety and efficacy of atezolizumab in combination with carboplatin plus etoposide in patients who have ES-SCLC and are chemotherapy-naive for their extensive-stage disease.

Timeline

Start
2019-08-12
Primary completion
2023-07-13
Completion
2023-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous